Cargando…

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers

Detalles Bibliográficos
Autores principales:	Tober-Lau, Pinkus, Schwarz, Tatjana, Vanshylla, Kanika, Hillus, David, Gruell, Henning, Suttorp, Norbert, Landgraf, Irmgard, Kappert, Kai, Seybold, Joachim, Drosten, Christian, Klein, Florian, Kurth, Florian, Sander, Leif Erik, Corman, Victor Max
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528470/ https://www.ncbi.nlm.nih.gov/pubmed/34687656 http://dx.doi.org/10.1016/S2213-2600(21)00456-2

Ejemplares similares

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
por: Hillus, David, et al.
Publicado: (2021)

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
por: Gruell, Henning, et al.
Publicado: (2022)

Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany
por: Schwarz, Tatjana, et al.
Publicado: (2021)

Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
por: Tober-Lau, Pinkus, et al.
Publicado: (2022)

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
por: Gruell, Henning, et al.
Publicado: (2022)

Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults
por: Vanshylla, Kanika, et al.
Publicado: (2022)

Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis
por: Schrezenmeier, Eva, et al.
Publicado: (2021)

SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
por: Gruell, Henning, et al.
Publicado: (2022)

Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study
por: Mühlemann, Barbara, et al.
Publicado: (2021)

Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February–March 2021
por: Tober-Lau, Pinkus, et al.
Publicado: (2021)

Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19
por: Thibeault, Charlotte, et al.
Publicado: (2023)

Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody
por: Meijers, Matthijs, et al.
Publicado: (2021)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
por: Bauernfeind, Stilla, et al.
Publicado: (2021)

Antibody-mediated neutralization of SARS-CoV-2
por: Gruell, Henning, et al.
Publicado: (2022)

Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1
por: LaMont, Colin, et al.
Publicado: (2022)

Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study
por: Lingscheid, Tilman, et al.
Publicado: (2022)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
por: Zurac, Sabina, et al.
Publicado: (2022)

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults
por: Priddy, Frances H., et al.
Publicado: (2022)

Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
por: Muñoz, Flor M., et al.
Publicado: (2023)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
por: Payne, Rebecca P., et al.
Publicado: (2021)

Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
por: Valentini, Diletta, et al.
Publicado: (2022)

Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases
por: Leung, Daniel, et al.
Publicado: (2023)

Monkeypox in-patients with severe anal pain
por: Pfäfflin, Frieder, et al.
Publicado: (2022)

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
por: Peled, Yael, et al.
Publicado: (2022)

Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
por: Naruse, Hiroyuki, et al.
Publicado: (2021)

Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
por: Karampitsakos, Theodoros, et al.
Publicado: (2022)

Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis
por: Michos, Athanasios, et al.
Publicado: (2022)

Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID‐19 vaccines in Hong Kong
por: Mok, Chris Ka Pun, et al.
Publicado: (2021)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
por: Murdoch, Louise, et al.
Publicado: (2023)

CD34T+ Humanized Mouse Model to Study Mucosal HIV-1 Transmission and Prevention
por: Vanshylla, Kanika, et al.
Publicado: (2021)

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
por: Ligumsky, Hagai, et al.
Publicado: (2022)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient
por: Agrati, Chiara, et al.
Publicado: (2021)

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer
por: Funakoshi, Yohei, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru
por: Vargas-Herrera, Natalia, et al.
Publicado: (2022)

Lactobacilli Expressing Broadly Neutralizing Nanobodies against HIV-1 as Potential Vectors for HIV-1 Prophylaxis?
por: Kalusche, Sarah, et al.
Publicado: (2020)

Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon
por: Moghnieh, Rima, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r844oru1q4n8leu85scebicqbq